GP73 Antibody (G-2): sc-398230

GP73 Antibody (G-2) is a mouse monoclonal IgG3 antibody that detects GP73 in mouse samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). GP73, also known as Golgi phosphoprotein 2, GOLPH 2, or Golgi membrane protein, is a type II transmembrane protein predominantly located in the Golgi apparatus, where GP73 plays a crucial role in the post-translational modification of proteins synthesized in the rough endoplasmic reticulum. This function ensures proteins are properly modified and sorted for specific cellular functions, which is essential for maintaining cellular homeostasis and facilitating intercellular communication. Notably, GP73 levels increase significantly in individuals diagnosed with acute and chronic liver diseases, making GP73 a potential biomarker for liver dysfunction. The human GP73 gene has been mapped within a bacterial artificial chromosome and localized to chromosome 9q21.33, further underscoring GP73′s importance in health and disease. Anti-GP73 antibody (G-2) is an invaluable tool for researchers studying liver pathology and the Golgi apparatus′s role in protein processing.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

GP73 Antibody (G-2) References:

1. GP73 is upregulated by hepatitis C virus (HCV) infection and enhances HCV secretion.  |  Hu, L., et al. 2014. PLoS One. 9: e90553. PMID: 24608522
2. GP73 was upregulated in PBMC stimulated with ConA but failed to promote lymphocyte proliferation.  |  Wang, F., et al. 2015. Cell Biol Int. 39: 334-40. PMID: 25231014
3. GP73 represses host innate immune response to promote virus replication by facilitating MAVS and TRAF6 degradation.  |  Zhang, X., et al. 2017. PLoS Pathog. 13: e1006321. PMID: 28394926
4. The Value of GPC3 and GP73 in Clinical Diagnosis of Hepatocellular Carcinoma.  |  Jing, JS., et al. 2017. Clin Lab. 63: 1903-1909. PMID: 29226636
5. GP73 promotes epithelial-mesenchymal transition and invasion partly by activating TGF-β1/Smad2 signaling in hepatocellular carcinoma.  |  Yang, Y., et al. 2018. Carcinogenesis. 39: 900-910. PMID: 29365054
6. Clinical significance of fucosylated GP73 in the differential diagnosis of hepatocellular carcinoma.  |  Zhao, Y., et al. 2018. Int J Biol Markers. 33: 439-446. PMID: 30238841
7. GP73, a novel TGF-β target gene, provides selective regulation on Smad and non-Smad signaling pathways.  |  Yang, X., et al. 2019. Biochim Biophys Acta Mol Cell Res. 1866: 588-597. PMID: 30615900
8. GP73-mediated secretion of AFP and GP73 promotes proliferation and metastasis of hepatocellular carcinoma cells.  |  Liu, Y., et al. 2021. Oncogenesis. 10: 69. PMID: 34650031
9. GP73 level in patients with chronic hepatitis B: Relationship with liver biopsy, levels of ALT, AST and HBV DNA.  |  Atilla, A., et al. 2022. Indian J Pathol Microbiol. 65: 55-58. PMID: 35074966
10. The potential value of serum GP73 in the ancillary diagnosis and grading of liver cirrhosis.  |  Hui-Ling, C., et al. 2023. Scand J Clin Lab Invest. 83: 95-102. PMID: 36786815

The preferred GP73 antibody is GP73 Antibody (F-2): sc-365817.